RxDoctor Payments Data

Nael Tarakji, MD

Neurology · Flint, MINPI 1336241082

Payments from drug & device makers

$98,774in general payments, 2019–2025

Across 788 payments — averaging $125.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$79K
  • Sanofi$11K
  • UCB, Inc.$2K
  • Biogen$996
  • Novartis$709
  • Amgen$634
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$3,6754%
  • Speaking & faculty fees$80,54882%
  • Travel & lodging$2,7663%
  • Food & beverage$11,75912%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,774 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$391,639
Medicare patients
384
Services billed
2,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine12$295,130
Kesimpta PenOfatumumab26$280,699
TysabriNatalizumab11$98,047
BriviactBrivaracetam58$81,991
AptiomEslicarbazepine Acetate30$70,844
VraylarCariprazine Hcl49$68,638
GlatopaGlatiramer Acetate11$41,613
Nurtec OdtRimegepant Sulfate15$25,691
RexultiBrexpiprazole16$25,057
Aimovig AutoinjectorErenumab-Aooe31$24,262
Lacosamide167$16,415
XcopriCenobamate13$15,613
Rivastigmine44$11,557
Divalproex Sodium ErDivalproex Sodium308$11,505
Duloxetine Hcl537$9,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$282$320,82027 claims
BiogenTysabri$996$98,04711 claims
UCB, Inc.Briviact$1,967$81,99158 claims
Sunovion Pharmaceuticals Inc.Aptiom$173$70,84430 claims
AbbVieVraylar$78,604$68,63849 claims
Otsuka America Pharmaceutical, Inc.Rexulti$162$25,05716 claims
SK Life Science, Inc.Xcopri$157$15,61313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →